Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma

Journal of Medical and Dental Sciences

Volumn 52, Issue 4, 2005, Pages 189-193

  Takeshita, Emiko ^a   Osanai, Takayuki ^a   Higuchi, Tetsuro ^a   Soumaoro, Labile Togba ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Breast carcinoma; Cyclooxygenase 2; Histological grade

Indexed keywords

CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MIDDLE AGED; PAGET NIPPLE DISEASE; PAPILLARY CARCINOMA; PATHOLOGY;

ADENOCARCINOMA; ADENOCARCINOMA, SCIRRHOUS; ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PAPILLARY; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 33344467996     PISSN: 13428810     EISSN: 13428810     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Thun MJ, Namboodiri MM,Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
2. Baron JA, Cole BR Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899.
3. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-890.
4. Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997;18:30-34.
5. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
6. Jacoby RF, Seibert K, Cole CE, et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
7. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
8. Higuchi T, Iwama T, Yoshinaga K, et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-4760.
9. Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
10. Kase S, Osaki M, Honjo S, et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004;23:301-307.
11. Nam KT, Hahm KB, Oh SY, et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 2004;10:8105-8113.
12. Uefuji K, Ichikura T, Shinomiya N, et al. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 2000;20:4279-4284.
13. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-2645.
14. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994.
15. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
16. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
17. Tsujii M, Kawano S,DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340.
18. Singh B,Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 2002;108:173-179.
19. Khuder SA,Mutgi AB. Breast cancer and NSAID use:a meta-analysis. Br J Cancer 2001;84:1188-1192.
20. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs:prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-6101.
21. Cotterchio M, Kreiger N, Sloan M, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-1217.
22. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103.
23. Basu GD, Pathangey LB, Tinder TL, et al. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004;2:632-642.
24. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460.
25. Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35.
26. Liu XH,Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125-5127.
27. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
28. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215-3221.
29. Singh Ranger G, Jewell A, Thomas V, et al. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 2004;88:100-103.
30. Witton CJ, Hawe SJ, Cooke TG, et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004;45:47-54.
31. Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expressions significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471.
32. Frierson HF, Jr., Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-198.
33. Taguchi T, Horino T,Ota J. Factors influencing on the prognosis in breast cancer. Gan To Kagaku Ryoho 1988;15:2043-2049. (in Japanese)
34. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998;58:4823-4826.
35. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001;91:1876-1881.
36. Sato T, Yoshinaga K, Okabe S, et al. Cyclooxygenase-2 expression in colorectal adenomas. Dis Colon Rectum 2003;46:786-792.
37. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987.
38. Wulfing P, Diallo R, Muller C, et al. Analysis of cyclooxygenase-2 expression in human breast cancer:high throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003;129:375-382.
39. Costa C, Soares R, Reis-Filho JS, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429-434.
40. Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-1681.
41. Davies G, Salter J, Hills M, et al. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003;9:2651-2656.
42. Shim V, Gauthier ML, Sudilovsky D, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003;63:2347-2350.
43. O'Reilly SM, Camplejohn RS, Millis RR, et al. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990;26:1035-1038.
44. Spizzo G, Gastl G, Wolf D, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003;88:574-578.
45. O'Connor JK, Avent J, Lee RJ, et al. Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:1034-1040.
46. Shattuck-Brandt RL, Varilek GW, Radhika A, et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000;118:337-345.
47. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000;156:545-553.
48. Sonoshita M, Takaku K, Oshima M, et al. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002;62:6846-6849.
49. Sato T, Yoshinaga K, Okabe S, et al. Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas. Jpn J Clin Oncol 2003;33:631-635.
50. Singh-Ranger G, Mokbel K. Current concepts in cyclooxygenase inhibition in breast cancer. J Clin Pharm Ther 2002;27:321-327.